Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000252

Drug Information
NameMesoridazine
Synonyms10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfinyl phenothiazine; BSPBio_000517; Lidanar; 10-[2(1-Methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)phenothiazine; Mesoridazine [USAN:BAN:INN]; Mesoridazina [INN-Spanish]; Calodal; UNII-5XE4NWM740; Lidanil; NCGC00163157-02; Phenothiazine, 10-(2-(1-methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)-; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfinyl)-10H-phenothiazine; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-methylsulfinyl phenothiazine; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)-phenothiazine; 10H-Phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylsulfinyl)-; LS-105603; Mesoridazinum; HSDB 3357; mesoridazine; Mesoridazina; THD-2-SO; CHEBI:248004; CID4078; CHEMBL1088; T-2-SO; Phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylsulfinyl)-; C07143; NCGC00163157-03; 10H-Phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-; D02671; TPS 23; Thioridazien thiomethyl sulfoxide; Tps23; TPS-23; Mesoridazine (USAN/INN); Serentil Concentrate; NCI60_001547; BPBio1_001167; Thioridazine-2-sulfoxide; WLN: T C666 BN ISJ ESO&1 B2- BT6NTJ A; AB00513854; D008653; BPBio1_000569; CHEBI:6780; L000852; Thioridazine thiomethyl sulfoxide; Mesoridazinum [INN-Latin]; 5588-33-0; 10-(2-(1-Methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-10H-phenothiazine; Serentil; NSC 186066; HMS2090H22; Biomol-NT_000013; NCGC00163157-01; AC1L1HD1; DB00933; Prestwick3_000529; Prestwick2_000529; Lidanar (TN); C21H26N2OS2; SPBio_002438; Prestwick1_000529; NC-123; BRD-A14395271-074-03-8; 10-(2(1-Methyl-2-piperidyl)ethyl)-2-(methylsulfinyl)phenothiazine; 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine; NSC186066; Thioridazine monosulfoxide analog; BRD-A14395271-001-01-5
Trade NameSerentil
CompanyNorvatis Phamaceuticals Corporation
IndicationSchizophrenia
[ICD9: 295   ICD10: F20]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-
21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H
3
InChIKeySLVMESMUVMCQIY-UHFFFAOYSA-N
Canonical SMILESCN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C    
Therapeutic ClassAntipsychotic Agents
CAS NumberCAS 5588-33-0
FormulaC21H26N2OS2
PubChem Compound IDCID 4078.
PubChem Substance IDSID 9352.
SuperDrug ATC IDN05AC03
SuperDrug CAS ID005588330;
TargetD(2) dopamine receptorAgonist[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016774 To Reference
Ref 2Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. Epub 2005 Aug 31. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543